Compare OGN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | ANIP |
|---|---|---|
| Founded | 1923 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2020 | 1999 |
| Metric | OGN | ANIP |
|---|---|---|
| Price | $6.11 | $74.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $11.75 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 3.0M | 345.1K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.72 | ★ 3.32 |
| Revenue | ★ $6,216,000,000.00 | $206,547,000.00 |
| Revenue This Year | $0.42 | $23.05 |
| Revenue Next Year | $1.67 | $14.08 |
| P/E Ratio | ★ $8.38 | $22.52 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $6.03 | $56.71 |
| 52 Week High | $15.36 | $99.50 |
| Indicator | OGN | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 45.15 |
| Support Level | N/A | $71.29 |
| Resistance Level | $7.87 | $77.47 |
| Average True Range (ATR) | 0.21 | 2.40 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 26.54 | 54.64 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.